Azitra is trading at $0.77, down 5.09%, with no confirmed company-specific announcement explaining its November 5 pre-market decline. - The latest identified company releases predate this session: October 26 cosmetic-study results and an October 29 expansion of trial eligibility. - Biotech was higher, while major index signals were mixed; neither clearly explains the decline. - Shares fell 7.71% on November 4 after gains on November 2 and 3.